Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102 Sep 28, 2017
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa Aug 29, 2017
Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights Aug 15, 2017
Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa Jul 18, 2017
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program Jun 29, 2017
Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa May 30, 2017
